• Claim your 0.5hr CE/CME Credit Here

  • What best describes your title?*
  • If MD/DO
  • If RN/NP
  • If PharmD
  • If PharmD, DOB
     - -
    2 digit month, 2 digit day, 4 digit year
  • Where are you based?
  • How did you FIRST hear about our tweetorials?
  • 1. Vutrisiran has been associated with improvements in all of the following outcomes compared to placebo, EXCEPT:*

  • Answer: D – Declines in hepatic function. Thankfully, the liver is not typically affected by ATTR-CM. Vutrisiran has been associated with improvements in outcome vs. placebo in all of the other parameters, as well as cardiovascular events, 6-minute walk distance, NYHA Class, and cardiac biomarkers.

  • 2. All of these agents work by lowering circulating TTR levels EXCEPT:*

  • Answer: B – Tafamidis. Tafamidis is a ‘stabilizer’, meaning it stabilizes the normal circulating form of TTR, thus making deposition as amyloid fibrils less likely. Vutrisiran, Nex-z, and nucresiran all work by lowering the liver’s production of TTR, though to date the only one approved for ATTR-CM (and ATTR-PN) is vutrisiran.

  • 3. Did you follow the entire tweetorial?*
  • 4. Did you find this to be an effective learning tool?*
  • 6. How will this program change your practice?*
  • 7. Will you recommend @cardiomet_CE and/or this website to your colleagues?*
  •  - -
    2 digit month, 2 digit day, 4 digit year
  • Should be Empty: